Stocks · Health care · Biological Products, (No Diagnostic Substances)

Tarsus Pharmaceuticals, Inc.

TARS Clue Score56

United States Fiscal year ends December CIK 0001819790 Results filed 3 Nov 2026

Add to watchlist

What the insiders did Net selling

Individual transactions

Insider

Date

Role

Action

Price

Amount

Andrew D. Goldberg

15 Dec 2023

Director

Buy

1,000

$18.96

$18.96K

Elizabeth Yeu Lin

15 Aug 2023

Director

Buy indirect

9,506

$16.80

$159.70K

Elizabeth Yeu Lin

14 Sep 2022

Director

Buy indirect

6,360

$16.29

$103.60K

Elizabeth Yeu Lin

14 Sep 2022

Director

Buy indirect

12,040

$16.03

$193.00K

Michael Ackermann

5 May 2022

Director

Buy indirect

100,000

$13.50

$1.35M

Showing 250 of 274 transactions. The figures above use every one of them.

What was left out

Form 4 filings counted 304

Amendments (4/A) skipped 0

Filings about a different issuer 0

Unreadable filings 0

Joint filings 8

Sales on a Rule 10b5-1 plan 64

Sales straight out of an exercise 5

Sales at will 191

Transactions with no price 0

Shares from compensation/vesting 11,493,487

Sales filed before the plan box existed 99

History held since 20 Oct 2020